{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:42:57Z","timestamp":1791654177204,"version":"4.3.4"},"reference-count":161,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000855","name":"University of Birmingham","doi-asserted-by":"publisher","award":["RF-6511848"],"award-info":[{"award-number":["RF-6511848"]}],"id":[{"id":"10.13039\/501100000855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000855","name":"University of Birmingham","doi-asserted-by":"publisher","award":["RGNS 64-157"],"award-info":[{"award-number":["RGNS 64-157"]}],"id":[{"id":"10.13039\/501100000855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017170","name":"Thailand Science Research and Innovation","doi-asserted-by":"publisher","award":["CRD42020162460"],"award-info":[{"award-number":["CRD42020162460"]}],"id":[{"id":"10.13039\/501100017170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ajog.2023.03.032","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T10:42:01Z","timestamp":1680000121000},"page":"222-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"229","author":[{"given":"Piya","family":"Chaemsaithong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda M.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noppadol","family":"Chaiyasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cuenca-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Plasencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-4130","authenticated-orcid":false,"given":"Liona C.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2023.03.032_bib1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/jhh.2017.61","article-title":"Placental growth factor and pre-eclampsia","volume":"31","author":"Chau","year":"2017","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ajog.2023.03.032_bib2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nm731","article-title":"Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1","volume":"8","author":"Luttun","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.RES.0000057997.77714.72","article-title":"VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism","volume":"92","author":"Pipp","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.ajog.2023.03.032_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0002-9378(98)70021-3","article-title":"Preeclampsia is associated with reduced serum levels of placenta growth factor","volume":"179","author":"Torry","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2023.03.032_bib8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ajog.2004.03.043","article-title":"Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award","volume":"190","author":"Chaiworapongsa","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.AOG.0000249609.04831.7c","article-title":"Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review","volume":"109","author":"Widmer","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14767050400028816","article-title":"Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia","volume":"17","author":"Chaiworapongsa","year":"2005","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050701830480","volume":"21","author":"Romero","year":"2008","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/uog.6244","article-title":"Maternal serum placental growth factor at 11\u00a0+ 0 to 13\u00a0+ 6 weeks of gestation in the prediction of pre-eclampsia","volume":"32","author":"Akolekar","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013263","article-title":"Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies","volume":"5","author":"Powers","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2023.03.032_bib14","doi-asserted-by":"crossref","first-page":"S1035","DOI":"10.1016\/j.ajog.2021.11.1350","article-title":"Discovery of antiangiogenic factors in the pathogenesis of preeclampsia","volume":"226","author":"Karumanchi","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/14767050902994754","article-title":"A\u00a0prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia","volume":"22","author":"Kusanovic","year":"2009","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/uog.7628","article-title":"Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks","volume":"35","author":"Poon","year":"2010","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/14767058.2011.589932","article-title":"Maternal plasma concentrations of angiogenic\/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia","volume":"24","author":"Chaiworapongsa","year":"2011","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib18","doi-asserted-by":"crossref","first-page":"287.e1","DOI":"10.1016\/j.ajog.2013.01.016","article-title":"Maternal plasma concentrations of angiogenic\/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia","volume":"208","author":"Chaiworapongsa","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000341264","article-title":"Competing risks model in early screening for preeclampsia by biophysical and biochemical markers","volume":"33","author":"Akolekar","year":"2013","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2023.03.032_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000359968","article-title":"Competing risks model\u00a0in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation","volume":"35","author":"Lai","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2023.03.032_bib21","doi-asserted-by":"crossref","first-page":"619.e1","DOI":"10.1016\/j.ajog.2015.11.016","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks\u2019 gestation","volume":"214","author":"Gallo","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks\u2019 gestation","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib23","doi-asserted-by":"crossref","first-page":"650.e1","DOI":"10.1016\/j.ajog.2019.09.041","article-title":"Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population","volume":"221","author":"Chaemsaithong","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib24","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.ajog.2018.11.1087","article-title":"Predictive performance of the competing risk model in screening for preeclampsia","volume":"220","author":"Wright","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib25","doi-asserted-by":"crossref","first-page":"197.e1","DOI":"10.1016\/j.ajog.2018.10.092","article-title":"Two-stage screening for preterm preeclampsia at 11-13 weeks\u2019 gestation","volume":"220","author":"Wright","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib26","doi-asserted-by":"crossref","first-page":"374.e1","DOI":"10.1016\/j.ajog.2019.10.101","article-title":"First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia","volume":"222","author":"Nzelu","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajog.2019.11.1247","article-title":"The competing risk approach for prediction of preeclampsia","volume":"223","author":"Wright","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib28","doi-asserted-by":"crossref","first-page":"608.e1","DOI":"10.1016\/j.ajog.2020.01.020","article-title":"A\u00a0new model for screening for early-onset preeclampsia","volume":"222","author":"Serra","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib29","doi-asserted-by":"crossref","first-page":"204.e1","DOI":"10.1016\/j.ajog.2020.08.008","article-title":"Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study","volume":"224","author":"Boutin","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ajog.2021.04.239","article-title":"Competing risks model for prediction of preeclampsia","volume":"225","author":"Wright","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib31","doi-asserted-by":"crossref","first-page":"618.e1","DOI":"10.1016\/j.ajog.2022.05.043","article-title":"Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction","volume":"227","author":"Agrawal","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib32","doi-asserted-by":"crossref","first-page":"S1071","DOI":"10.1016\/j.ajog.2020.07.020","article-title":"First trimester preeclampsia screening and prediction","volume":"226","author":"Chaemsaithong","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib33","doi-asserted-by":"crossref","first-page":"294.e1","DOI":"10.1016\/j.ajog.2022.03.007","article-title":"Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia","volume":"227","author":"Lai","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib34","doi-asserted-by":"crossref","first-page":"S1019","DOI":"10.1016\/j.ajog.2020.10.022","article-title":"Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders","volume":"226","author":"Rana","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib35","doi-asserted-by":"crossref","first-page":"S1048","DOI":"10.1016\/j.ajog.2020.09.046","article-title":"The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia","volume":"226","author":"Verlohren","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.119.13360","article-title":"Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis","volume":"74","author":"Agrawal","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.117.10182","article-title":"Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine Kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study","volume":"71","author":"Agrawal","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review\u00a0and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2023.03.032_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.preghy.2018.06.017","article-title":"Clinical implementation of the sFlt-1\/PlGF ratio to identify preeclampsia and fetal growth restriction: a prospective cohort study","volume":"13","author":"Herraiz","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2023.03.032_bib40","first-page":"1","article-title":"ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","article-title":"The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice","volume":"27","author":"Magee","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2023.03.032_bib42","first-page":"529","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann\u00a0Intern Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib44","series-title":"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0","article-title":"Chapter 10: Analysing and Presenting Results","author":"Macaskill","year":"2010"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2023.03.032_bib45","first-page":"S48","article-title":"Regression methods for meta-analysis of diagnostic test data","volume":"2","author":"Rutter","year":"1995","journal-title":"Acad Radiol"},{"key":"10.1016\/j.ajog.2023.03.032_bib46","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/sim.942","article-title":"A\u00a0hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations","volume":"20","author":"Rutter","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-149-12-200812160-00008","article-title":"Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy","volume":"149","author":"Leeflang","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib48","first-page":"211","article-title":"metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression","volume":"9","author":"Harbord","year":"2009","journal-title":"Stata"},{"key":"10.1016\/j.ajog.2023.03.032_bib49","unstructured":"StataCorp. Stata Statistical Software: Release 16. StataCorp LLC, College Station, TX; 2019."},{"key":"10.1016\/j.ajog.2023.03.032_bib50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10641955.2016.1167219","article-title":"Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort","volume":"35","author":"Andersen","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.ajog.2023.03.032_bib51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/uog.15812","article-title":"Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks\u2019 gestation","volume":"48","author":"Andrietti","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2018.04.010","article-title":"Predictive value of sFlt-1, PlGF, sFlt-1\/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy","volume":"12","author":"Birdir","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2023.03.032_bib53","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ajo.13113","article-title":"Prediction of preterm pre-eclampsia at midpregnancy using a multivariable screening algorithm","volume":"60","author":"Black","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib54","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3109\/14767058.2015.1048431","article-title":"The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia","volume":"29","author":"Chaiworapongsa","year":"2016","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijgo.2008.02.016","article-title":"Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry","volume":"102","author":"Diab","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2023.03.032_bib56","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/pd.4198","article-title":"Second-trimester uterine artery Doppler, PlGF, sFlt-1, sEndoglin, and lipid-related markers for predicting preeclampsia in a high-risk population","volume":"33","author":"Diguisto","year":"2013","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ajog.2023.03.032_bib57","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1701-2163(15)30511-9","article-title":"Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1\/PlGF ratio before the onset of early severe preeclampsia","volume":"36","author":"Doherty","year":"2014","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2023.03.032_bib58","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.ajog.2006.11.002","article-title":"Identification of patients at risk for early onset and\/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor","volume":"196","author":"Espinoza","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000362518","article-title":"Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation","volume":"36","author":"Larroca","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2023.03.032_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejogrb.2011.12.031","article-title":"Combination of uterine artery Doppler velocimetry and maternal serum placental growth factor estimation in predicting occurrence of pre-eclampsia in early second trimester pregnancy: a prospective cohort study","volume":"161","author":"Ghosh","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2023.03.032_bib61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00404-012-2662-2","article-title":"Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?","volume":"287","author":"Ghosh","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2023.03.032_bib62","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/uog.23568","article-title":"Maternal cardiac function at 19-23 weeks\u2019 gestation in prediction of pre-eclampsia","volume":"57","author":"Gibbone","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib63","first-page":"19","article-title":"Serum soluble FMS-like tyrosine kinase 1 and placental growth factor concentration as predictors of preeclampsia in high risk pregnant women","volume":"36","author":"Hanita","year":"2014","journal-title":"Malays J Pathol"},{"key":"10.1016\/j.ajog.2023.03.032_bib64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/14767058.2015.1012063","article-title":"Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population","volume":"29","author":"Kienast","year":"2016","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijgo.2005.02.008","article-title":"Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry","volume":"89","author":"Madazli","year":"2005","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2023.03.032_bib66","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s13224-015-0793-7","article-title":"A\u00a0prospective study of placental growth factor assay as a novel biomarker in predicting early-onset preeclampsia in high-risk patients","volume":"66","author":"Mathur","year":"2016","journal-title":"J\u00a0Obstet Gynaecol India"},{"key":"10.1016\/j.ajog.2023.03.032_bib67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/14767058.2017.1373760","article-title":"Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)\/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin","volume":"32","author":"Navaratnam","year":"2019","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib68","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/HYPERTENSIONAHA.111.174417","article-title":"Threshold of soluble fms-like tyrosine kinase 1\/placental growth factor ratio for the imminent onset of preeclampsia","volume":"58","author":"Ohkuchi","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib69","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/uog.19111","article-title":"Screening for pre-eclampsia at 35-37 weeks\u2019 gestation","volume":"52","author":"Panaitescu","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2393-14-35","article-title":"Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy","volume":"14","author":"Park","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.ajog.2023.03.032_bib71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/uog.23517","article-title":"Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks\u2019 gestation","volume":"57","author":"Sarno","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/jwh.2010.2378","article-title":"Early prediction of preeclampsia in high-risk women","volume":"20","author":"Shaker","year":"2011","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.ajog.2023.03.032_bib73","doi-asserted-by":"crossref","first-page":"268.e1","DOI":"10.1016\/j.ajog.2008.06.071","article-title":"Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and\/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?","volume":"199","author":"Sibai","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib74","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.HYP.0000258404.21552.a3","article-title":"Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion","volume":"49","author":"Stepan","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/uog.17307","article-title":"Comparison of screening for pre-eclampsia at 31-34 weeks\u2019 gestation by sFlt-1\/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF","volume":"49","author":"Tan","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jogoh.2017.10.007","article-title":"Angiogenic factors sFlt-1 and PlGF in preeclampsia: prediction of risk and prognosis in a high-risk obstetric population","volume":"47","author":"Tardif","year":"2018","journal-title":"J\u00a0Gynecol Obstet Hum Reprod"},{"key":"10.1016\/j.ajog.2023.03.032_bib77","doi-asserted-by":"crossref","first-page":"87.e1","DOI":"10.1016\/j.ajog.2016.02.016","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks\u2019 gestation","volume":"215","author":"Tsiakkas","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/uog.15663","article-title":"Biophysical and biochemical markers at 35-37 weeks\u2019 gestation in the prediction of adverse perinatal outcome","volume":"47","author":"Vali\u00f1o","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib79","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.preghy.2015.09.004","article-title":"Accuracy of angiogenic biomarkers at \u2a7d20weeks\u2019 gestation in predicting the risk of pre-eclampsia: a WHO multicentre study","volume":"5","author":"Widmer","year":"2015","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2023.03.032_bib80","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/uog.19099","article-title":"Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks\u2019 gestation","volume":"52","author":"Litwinska","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/uog.21869","article-title":"From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: comprehensive approach","volume":"55","author":"Poon","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib82","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/jch.13302","article-title":"Risk factors for adverse maternal and perinatal outcomes in women with preeclampsia: analysis of 1396 cases","volume":"20","author":"Li","year":"2018","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ajog.2023.03.032_bib83","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.ajog.2019.01.235","article-title":"Prediction of imminent preeclampsia at 35-37 weeks gestation","volume":"220","author":"Ciobanu","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib84","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00404-015-3671-8","article-title":"Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1\/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies","volume":"292","author":"Liu","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2023.03.032_bib85","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1161\/HYPERTENSIONAHA.117.10150","article-title":"Placental growth factor as a prognostic tool in women with hypertensive disorders of pregnancy: a systematic review","volume":"70","author":"Ukah","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib86","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00404-017-4302-3","article-title":"Dual-cutoff of sFlt-1\/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis","volume":"295","author":"Zhao","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2023.03.032_bib87","first-page":"1","article-title":"Angiogenic factors and the risk of preeclampsia: a systematic review and meta-analysis","volume":"17","author":"Veisani","year":"2019","journal-title":"Int J Reprod Biomed"},{"key":"10.1016\/j.ajog.2023.03.032_bib88","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/AOG.0000000000004149","article-title":"Biomarkers and the prediction of adverse outcomes in preeclampsia: a systematic review and meta-analysis","volume":"137","author":"Lim","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib89","doi-asserted-by":"crossref","first-page":"615.e1","DOI":"10.1016\/j.ajog.2022.04.015","article-title":"Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology","volume":"227","author":"Romero","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib90","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1055\/s-0035-1557924","article-title":"Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of DGGG (S1-level, AWMF Registry No. 015\/018, December 2013)","volume":"75","author":"Stepan","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.ajog.2023.03.032_bib91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejogrb.2016.08.036","article-title":"Italian Advisory Board: sFlt-1\/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management","volume":"206","author":"Di Martino","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2023.03.032_bib92","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajog.2023.03.032_bib94","first-page":"145","article-title":"Hypertensive diseases in preganncy","volume":"83","author":"Vik","year":"2018","journal-title":"Czech Gynecol"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2023.03.032_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and\u00a0prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2023.03.032_bib96","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.ajog.2019.09.003","article-title":"Placental growth factor predicts time to delivery\u00a0in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study","volume":"222","author":"Barton","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2023.03.032_bib97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13763","volume":"154","author":"Poon","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2023.03.032_bib98","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2021.05.043","article-title":"Electronic address: pubs@smfm.org. Executive summary: workshop on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine and the Preeclampsia Foundation","volume":"225","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib99","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajog.2020.11.007","article-title":"Performance of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio of \u226585 for ruling in preeclampsia within 4 weeks","volume":"224","author":"Cerdeira","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib100","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.ajog.2021.03.044","article-title":"Placental growth factor testing in the management of late preterm preeclampsia without severe features: a multicenter, randomized, controlled trial","volume":"225","author":"Peguero","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ajog.2021.11.1345","article-title":"Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1\/placental growth factor ratio \u226438: secondary analysis of the Interventional Study on Prediction of Preeclampsia\/eclampsia in Women with Suspected Preeclampsia","volume":"226","author":"Cerdeira","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/uog.17418","article-title":"Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks\u2019 gestation","volume":"50","author":"Litwinska","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/uog.17419","article-title":"Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks\u2019 gestation","volume":"50","author":"Panaitescu","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib104","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ajog.2023.03.032_bib105","doi-asserted-by":"crossref","first-page":"604.e1","DOI":"10.1016\/j.ajog.2018.09.036","article-title":"The clinical heterogeneity of preeclampsia is related to both placental\u00a0gene expression and placental histopathology","volume":"219","author":"Benton","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib106","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.ajog.2021.11.1356","article-title":"The etiology of preeclampsia","volume":"226","author":"Jung","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib107","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajog.2021.08.061","article-title":"Two physiological phenotypes in preeclampsia: do they really exist?","volume":"226","author":"Jha","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib108","doi-asserted-by":"crossref","first-page":"S1006","DOI":"10.1016\/j.ajog.2020.10.052","article-title":"Preeclampsia has two phenotypes which require different treatment strategies","volume":"226","author":"Masini","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib109","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajog.2021.09.006","article-title":"Reply: preeclampsia has 2 phenotypes that require different treatment strategies","volume":"227","author":"Masini","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1515\/jpm-2022-0433","article-title":"Molecular subclasses of preeclampsia characterized by a longitudinal maternal proteomics study: distinct biomarkers, disease pathways and options for prevention","volume":"51","author":"Than","year":"2023","journal-title":"J\u00a0Perinat Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib111","article-title":"Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood","author":"Chaiworapongsa","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib112","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1471-0528.2004.00071.x","article-title":"Is pre-eclampsia more than one disease?","volume":"111","author":"Vatten","year":"2004","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2023.03.032_bib113","doi-asserted-by":"crossref","first-page":"544.e1","DOI":"10.1016\/j.ajog.2013.08.019","article-title":"Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease","volume":"209","author":"Lisonkova","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib114","doi-asserted-by":"crossref","first-page":"517.e1","DOI":"10.1016\/j.ajog.2018.02.007","article-title":"Early and late preeclampsia are characterized by high cardiac output, but in the presence of fetal growth restriction, cardiac output is low: insights from a prospective study","volume":"218","author":"Tay","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib115","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/HYPERTENSIONAHA.120.14781","article-title":"Subtypes of preeclampsia: recognition and determining clinical usefulness","volume":"77","author":"Roberts","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib116","doi-asserted-by":"crossref","first-page":"S867","DOI":"10.1016\/j.ajog.2021.11.019","article-title":"Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia","volume":"226","author":"Robillard","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib117","doi-asserted-by":"crossref","first-page":"S963","DOI":"10.1016\/j.ajog.2020.10.023","article-title":"An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array","volume":"226","author":"Yagel","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib118","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.ajog.2015.08.042","article-title":"Why is placentation abnormal in preeclampsia?","volume":"213","author":"Fisher","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib119","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajog.2019.05.044","article-title":"Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes","volume":"221","author":"Brosens","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajog.2019.01.239","article-title":"Preeclampsia: the role of persistent endothelial cells in uteroplacental arteries","volume":"221","author":"Brosens","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib121","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ajog.2019.07.010","article-title":"Placental bed research: II. Functional and immunological investigations of the placental bed","volume":"221","author":"Harris","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib122","doi-asserted-by":"crossref","first-page":"S895","DOI":"10.1016\/j.ajog.2020.09.026","article-title":"Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia","volume":"226","author":"Staff","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib123","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/uog.22107","article-title":"Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: systematic review and meta-analysis","volume":"57","author":"Dall\u2019Asta","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib124","first-page":"l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"Burton","year":"2019","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.ajog.2023.03.032_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223888","article-title":"Increased BMI has a linear association with late-onset preeclampsia: a population-based study","volume":"14","author":"Robillard","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2023.03.032_bib126","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1515\/jpm.2011.098","article-title":"Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia","volume":"39","author":"Ogge","year":"2011","journal-title":"J\u00a0Perinat Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ajog.2022.08.010","article-title":"Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease","volume":"228","author":"Redline","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib129","doi-asserted-by":"crossref","first-page":"580.e1","DOI":"10.1016\/j.ajog.2019.02.034","article-title":"Aspirin delays the development of preeclampsia","volume":"220","author":"Wright","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajog.2019.08.047","article-title":"Does low-dose aspirin initiated before 11 weeks\u2019 gestation reduce the rate of preeclampsia?","volume":"222","author":"Chaemsaithong","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib131","doi-asserted-by":"crossref","first-page":"S1108","DOI":"10.1016\/j.ajog.2020.08.045","article-title":"Prevention of preeclampsia with aspirin","volume":"226","author":"Rolnik","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib132","article-title":"Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials","author":"Liu","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib133","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ajog.2022.09.046","article-title":"Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis","volume":"228","author":"Richards","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib134","doi-asserted-by":"crossref","first-page":"S1120","DOI":"10.1016\/j.ajog.2021.10.038","article-title":"When to give aspirin to prevent preeclampsia: application of Bayesian decision theory","volume":"226","author":"Wright","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib135","doi-asserted-by":"crossref","first-page":"629.e1","DOI":"10.1016\/j.ajog.2015.11.015","article-title":"Maternal plasma angiogenic index-1 (placental growth factor\/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study","volume":"214","author":"Korzeniewski","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib136","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric--Fetal Pharmacology Research Units Network\u2217. Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib137","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/14767058.2015.1129779","article-title":"Pravastatin for the prevention of adverse pregnancy outcome: preeclampsia and more?","volume":"30","author":"Chaiworapongsa","year":"2017","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib139","doi-asserted-by":"crossref","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A\u00a0randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"Costantine","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib140","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia","volume":"144","author":"D\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2023.03.032_bib141","doi-asserted-by":"crossref","first-page":"S1157","DOI":"10.1016\/j.ajog.2020.09.014","article-title":"Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia","volume":"226","author":"Tong","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib142","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajog.2021.10.014","article-title":"Statins to prevent or treat preeclampsia: sometimes it is too late","volume":"226","author":"Voto","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib143","doi-asserted-by":"crossref","first-page":"S1171","DOI":"10.1016\/j.ajog.2020.08.040","article-title":"The role of statins in the prevention of preeclampsia","volume":"226","author":"Smith","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib144","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ajog.2021.10.011","article-title":"Reply: timing of pravastatin initiation for preeclampsia prevention","volume":"226","author":"Smith","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2023.03.032_bib146","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ajog.2023.03.032_bib147","doi-asserted-by":"crossref","first-page":"S1059","DOI":"10.1016\/j.ajog.2020.09.038","article-title":"Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"226","author":"Burwick","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib148","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble Fms-like tyrosine Kinase-1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadhani","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ajog.2023.03.032_bib149","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41581-019-0119-6","article-title":"Pre-eclampsia: pathogenesis, novel diagnostics and therapies","volume":"15","author":"Phipps","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ajog.2023.03.032_bib150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/HYPERTENSIONAHA.118.12380","article-title":"VEGF (vascular endothelial growth factor) functionalized magnetic beads in a microfluidic device to improve the angiogenic balance in preeclampsia","volume":"74","author":"Trapiella-Alfonso","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib151","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/HYPERTENSIONAHA.120.15112","article-title":"One step closer to a cure for preeclampsia?: boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1","volume":"76","author":"Cerdeira","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib152","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/HYPERTENSIONAHA.120.14974","article-title":"Affinity-enhanced multimeric VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) variants for specific adsorption of sFlt-1 to restore angiogenic balance in preeclampsia","volume":"76","author":"Matin","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2023.03.032_bib153","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ajog.2022.01.009","article-title":"Extracorporeal membrane oxygenation in pregnancy: details on novel therapies and cardiac, preeclampsia, and mood disorder complications","volume":"226","author":"Yin","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib154","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/uog.23640","article-title":"Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks\u2019 gestation","volume":"58","author":"Litwinska","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib155","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(09)61380-5","article-title":"Induced labour for pre-eclampsia and gestational hypertension","volume":"374","author":"Johnson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2023.03.032_bib156","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(09)60736-4","article-title":"Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks\u2019 gestation (HYPITAT): a multicentre, open-label randomised controlled trial","volume":"374","author":"Koopmans","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2023.03.032_bib157","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1471-2393-14-292","article-title":"Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis","volume":"14","author":"Stubert","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.ajog.2023.03.032_bib158","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(19)31963-4","article-title":"Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial","volume":"394","author":"Chappell","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2023.03.032_bib159","doi-asserted-by":"crossref","first-page":"154.e1","DOI":"10.1016\/j.ajog.2019.03.024","article-title":"Neonatal developmental and behavioral outcomes of immediate delivery versus expectant monitoring in mild hypertensive disorders of pregnancy: 2-year outcomes of the HYPITAT-II trial","volume":"221","author":"Zwertbroek","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib160","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ajog.2022.04.034","article-title":"Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis","volume":"227","author":"Beardmore-Gray","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib161","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1080\/14767058.2021.2022645","article-title":"Delivery outcomes after induction of labor among women with hypertensive disorders of pregnancy","volume":"35","author":"Hagans","year":"2022","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2023.03.032_bib162","doi-asserted-by":"crossref","first-page":"338.e1","DOI":"10.1016\/j.ajog.2022.08.045","article-title":"A\u00a0novel approach to joint prediction of preeclampsia and delivery timing using semicompeting risks","volume":"228","author":"Reeder","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2023.03.032_bib163","doi-asserted-by":"crossref","first-page":"457.e1","DOI":"10.1016\/j.ajog.2022.09.047","article-title":"The implications of the Fetal Medicine Foundation 35- to 36-week preeclampsia prediction competing-risk model on timing of birth","volume":"228","author":"von Dadelszen","year":"2023","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937823001965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937823001965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:37:04Z","timestamp":1762079824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937823001965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":161,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0002937823001965"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2023.03.032","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2023.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}